Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079270178> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2079270178 endingPage "2574" @default.
- W2079270178 startingPage "2567" @default.
- W2079270178 abstract "PURPOSE: Troxacitabine (Troxatyl, BCH-4556; BioChem Pharma Inc, Basingstoke, United Kingdom) is a novel synthetic l-nucleoside analog with activity against a broad range of human tumors in preclinical models. Preclinical toxicity suggested a predictable toxicity profile consistent with an agent of this class, with evidence of interspecies differences. We conducted a phase I study of troxacitabine given as a 30-minute infusion once every 21 days. PATIENTS AND METHODS: The starting dose of troxacitabine was 0.025 mg/m 2 , based on toxicology data from the most sensitive species studied (cynomolgus monkey). Doses were doubled until grade 1 skin or mucosal or grade 2 other toxicity was encountered. A modified Fibonacci scale was used. RESULTS: A total of 45 patients were enrolled at 13 dose levels. Most common nonhematologic side effects were skin rash (44%), lethargy (29%), nausea (24%), alopecia, dry skin (18%), anorexia (13%), neurosensory symptoms (13%), and hand-foot syndrome (13%). In patients treated with prednisone 25 mg/d orally for 5 days, starting on day 1, skin rash was less problematic. Two patients at 12.5 mg/m 2 experienced dose-limiting (grade 4) granulocytopenia. Confirmed partial responses were documented in one patient with previously untreated renal cell carcinoma with metastatic lung and bone lesions and in one patient with an unknown primary tumor. Eighteen patients had a best response of stable disease with a median duration of 5.1 months (range, 2.1 to 18.7 months). CONCLUSION: When given in this schedule, the maximum-tolerated dose of troxacitabine is 12.5 mg/m 2 , and the recommended dose for additional phase II studies is 10 mg/m 2 once every 21 days with steroid premedication." @default.
- W2079270178 created "2016-06-24" @default.
- W2079270178 creator A5000204204 @default.
- W2079270178 creator A5003643368 @default.
- W2079270178 creator A5008772349 @default.
- W2079270178 creator A5012084917 @default.
- W2079270178 creator A5039647179 @default.
- W2079270178 creator A5044291041 @default.
- W2079270178 creator A5050987784 @default.
- W2079270178 creator A5064078958 @default.
- W2079270178 creator A5067138875 @default.
- W2079270178 creator A5077260725 @default.
- W2079270178 date "2002-05-15" @default.
- W2079270178 modified "2023-10-16" @default.
- W2079270178 title "Phase I and Pharmacokinetic Study of Novel <scp>l</scp>-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days" @default.
- W2079270178 cites W1550111394 @default.
- W2079270178 cites W1939358691 @default.
- W2079270178 cites W2024382021 @default.
- W2079270178 cites W2115633225 @default.
- W2079270178 cites W4242609118 @default.
- W2079270178 doi "https://doi.org/10.1200/jco.2002.12.047" @default.
- W2079270178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12011137" @default.
- W2079270178 hasPublicationYear "2002" @default.
- W2079270178 type Work @default.
- W2079270178 sameAs 2079270178 @default.
- W2079270178 citedByCount "19" @default.
- W2079270178 crossrefType "journal-article" @default.
- W2079270178 hasAuthorship W2079270178A5000204204 @default.
- W2079270178 hasAuthorship W2079270178A5003643368 @default.
- W2079270178 hasAuthorship W2079270178A5008772349 @default.
- W2079270178 hasAuthorship W2079270178A5012084917 @default.
- W2079270178 hasAuthorship W2079270178A5039647179 @default.
- W2079270178 hasAuthorship W2079270178A5044291041 @default.
- W2079270178 hasAuthorship W2079270178A5050987784 @default.
- W2079270178 hasAuthorship W2079270178A5064078958 @default.
- W2079270178 hasAuthorship W2079270178A5067138875 @default.
- W2079270178 hasAuthorship W2079270178A5077260725 @default.
- W2079270178 hasConcept C112705442 @default.
- W2079270178 hasConcept C126322002 @default.
- W2079270178 hasConcept C197934379 @default.
- W2079270178 hasConcept C2777054765 @default.
- W2079270178 hasConcept C2777260799 @default.
- W2079270178 hasConcept C2778570526 @default.
- W2079270178 hasConcept C2780580376 @default.
- W2079270178 hasConcept C29730261 @default.
- W2079270178 hasConcept C71924100 @default.
- W2079270178 hasConcept C90924648 @default.
- W2079270178 hasConcept C98274493 @default.
- W2079270178 hasConceptScore W2079270178C112705442 @default.
- W2079270178 hasConceptScore W2079270178C126322002 @default.
- W2079270178 hasConceptScore W2079270178C197934379 @default.
- W2079270178 hasConceptScore W2079270178C2777054765 @default.
- W2079270178 hasConceptScore W2079270178C2777260799 @default.
- W2079270178 hasConceptScore W2079270178C2778570526 @default.
- W2079270178 hasConceptScore W2079270178C2780580376 @default.
- W2079270178 hasConceptScore W2079270178C29730261 @default.
- W2079270178 hasConceptScore W2079270178C71924100 @default.
- W2079270178 hasConceptScore W2079270178C90924648 @default.
- W2079270178 hasConceptScore W2079270178C98274493 @default.
- W2079270178 hasIssue "10" @default.
- W2079270178 hasLocation W20792701781 @default.
- W2079270178 hasLocation W20792701782 @default.
- W2079270178 hasOpenAccess W2079270178 @default.
- W2079270178 hasPrimaryLocation W20792701781 @default.
- W2079270178 hasRelatedWork W2041028278 @default.
- W2079270178 hasRelatedWork W2081385765 @default.
- W2079270178 hasRelatedWork W2090302698 @default.
- W2079270178 hasRelatedWork W2135191085 @default.
- W2079270178 hasRelatedWork W2516359773 @default.
- W2079270178 hasRelatedWork W3119264702 @default.
- W2079270178 hasRelatedWork W3130870762 @default.
- W2079270178 hasRelatedWork W4310874150 @default.
- W2079270178 hasRelatedWork W4382344715 @default.
- W2079270178 hasRelatedWork W622993943 @default.
- W2079270178 hasVolume "20" @default.
- W2079270178 isParatext "false" @default.
- W2079270178 isRetracted "false" @default.
- W2079270178 magId "2079270178" @default.
- W2079270178 workType "article" @default.